Foghorn Therapeutics Inc.
For the period ended Oct 30, 2025. Filed Oct 30, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 30, 2025 · Filed Oct 30, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.2 · Selective CBP Degrader Program
Selective CBP Degrader Program
CBP is an acetyltransferase that selectively targets a synthetic relationship established in EP300-mutated cancers, which includes endometrial, cervical, ovarian, bladder and colorectal cancer. Attempts to selectively drug CBP have been challenging due to the high level of similarity with EP300, and dose-limiting toxicities associated with dual inhibition of both CBP and EP300. CBP lineage dependencies are established in several cancers, including ER+ breast cancer.
Foghorn is advancing a Selective CBP degrader, on track to be Investigational New Drug (IND)-ready in 2026. Key updates include:
Highly potent and selective lead candidate CBPd-171 advancing to dose range finding toxicology studies in Q4 2025
Anti-tumor activity in EP300-mutant solid tumors and in CBP-dependent cancers, including promising potential in ER+ breast cancer
No significant impact on platelet counts and megakaryocytes spared with CBPd-171 dosing
Long Acting Injectable (LAI) formulation optimized for subcutaneous injection weekly or every
other week for convenient administration
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.